Dupixent vs Rinvoq
Side-by-side cost comparison based on Medicare Part D data
Dupixent
Dupilumab
Manufactured by Regeneron/Sanofi
Rinvoq
Upadacitinib
Manufactured by AbbVie
Dupixent costs 19% less per claim than Rinvoq ($2,819.00 vs $3,498.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Dupixent | Rinvoq |
|---|---|---|
| Avg Cost Per Claim | $2,819.00 | $3,498.00 |
| Total Medicare Spending | $4.4B | $2.3B |
| Total Beneficiaries | 245,000 | 92,000 |
| Total Claims | 1,560,000 | 648,000 |
| Annual Cost/Patient | $17,951.00 | $24,641.00 |
| Year-over-Year Change | +35.2% | +56.3% |
| Generic Available | No | No |
| Patent Expiration | Mar 28, 2031 | Aug 16, 2033 |
| Manufacturer | Regeneron/Sanofi | AbbVie |
| Condition | Autoimmune Diseases | Autoimmune Diseases |
| Generic Name | Dupilumab | Upadacitinib |
Dupixent vs Rinvoq: What the Data Shows
Dupixent (Dupilumab) and Rinvoq (Upadacitinib) are both used to treat autoimmune diseases. Based on Medicare Part D data, Dupixent costs $2,819.00 per claim, which is 19% less than Rinvoq at $3,498.00 per claim.
Medicare spent $4.4B on Dupixent and $2.3B on Rinvoq. In terms of patient reach, Dupixent serves more beneficiaries (245,000 vs 92,000).
Year-over-year spending changed +35.2% for Dupixent and +56.3% for Rinvoq. Dupixent saw significant spending growth, suggesting increased utilization or price increases. Rinvoq saw significant spending growth, suggesting increased utilization or price increases.
Neither drug currently has a generic version. Dupixent patent expires Mar 28, 2031. Rinvoq patent expires Aug 16, 2033.
Frequently Asked Questions
Dupixent is cheaper at $2,819.00 per claim, compared to $3,498.00 for Rinvoq. That makes Dupixent about 19% less expensive per claim based on Medicare Part D data.
Yes, both Dupixent and Rinvoq are used to treat autoimmune diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Neither drug currently has a generic version available. Dupixent patent expires Mar 28, 2031. Rinvoq patent expires Aug 16, 2033.
Medicare Part D spent $4.4B on Dupixent covering 245,000 beneficiaries, and $2.3B on Rinvoq covering 92,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.